Medicaid now covers lung cancer biomarker testing for low-income patients
H.R. 6320 — Improving Medicaid Precision and Cancer Test Act of 2025 · Filed by Josh Gottheimer (D-NJ) · 3 cosponsors · Introduced Nov 28, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires state Medicaid programs to cover lung cancer biomarker testing—diagnostic tests that identify genetic or protein markers in tumors to guide treatment—starting January 1, 2027. The bill amends the Social Security Act to add biomarker testing to the list of mandatory Medicaid-covered services, ensuring eligible low-income patients can access these tests without cost-sharing.
Why we flagged it
The bill's sole operative mechanism is to add a specific diagnostic service to the mandatory benefits list under Medicaid, expanding coverage for a precision oncology test. This is a straightforward public-health entitlement expansion.
What the text implies
- States will bear increased Medicaid expenditures for biomarker testing; federal matching funds will offset some but not all costs, creating a potential budget pressure on state programs.
- The January 1, 2027 effective date gives states ~2 years to establish billing, coding, and reimbursement infrastructure; implementation delays could affect access in early 2027.
The full analysis lists 4 implications of this text.
Who stands to gain
diagnostic laboratory companies (Guardant Health, Foundation Medicine, Myriad Genetics, etc.); hospital pathology departments; oncology practices offering biomarker-guided treatment